ACO REACH: An Innovative Step Towards Health Equity

By HEOR Staff Writer

October 29, 2023

Understanding ACO REACH and its Impact

Launched in January 2023, Accountable Care Organisation Realising Equity, Access, and Community Health (ACO REACH), initiated by the Centers for Medicare and Medicaid Services (CMS), has taken a strategic leap towards equity in healthcare. The model is designed to promote health equity through payment model design, data collection on social drivers of health, and financial incentives linked to equity.

A key feature of ACO REACH is the Health Equity Benchmark Adjustment (HEBA). This adjustment allows for increases or decreases in participants’ financial benchmarks based on the beneficiaries they serve. The goal? To remove the disincentives to serve marginalised populations by acknowledging the extra costs of caring for these groups.

Changes to HEBA Calculations in 2024

As we move into 2024, Medicare is taking on board stakeholder feedback and revising its approach to HEBA calculations. This change is significant, as it marks one of the first attempts to alter financial targets based on non-medical factors.

The way HEBA scores are calculated will also undergo changes. Currently, the HEBA is based on measures of individual beneficiary income and area-level social need. However, from next year, CMS will incorporate beneficiaries’ state ADI, a measure that ranks the social need in a beneficiary’s neighbourhood against the need in other neighbourhoods across a given state.

The implications of these changes are substantial. They represent a pragmatic way to improve policymakers’ ability to identify individuals with low-income and high health-related need.

In conclusion, ACO REACH is one of the first models to reflect a national call to action for health care stakeholders to go beyond traditional approaches to value-based payment and address equity. 

Reference url

Recent Posts

Safeguarding Access: Navigating Pharmaceutical Cost Pressures in Portugal

By João L. Carapinha

April 13, 2026

Pharmaceutical cost pressures are mounting in Portugal, with industry leaders warning that price increases for certain medicines appear inevitable in the medium term despite the government’s commitment to strict controls in the 2026 annual review. Global Cost Drivers Threaten Generic...
Inequality-Adjusted ICER: Enhancing Cost-Effectiveness in Health Technology Evaluation
The inequality-adjusted ICER offers a practical way to embed explicit trade-offs between maximising total population health and reducing health inequality directly into cost-effectiveness analysis. By dividing the conventional ICER by an inequality-adjusted ICER, analysts derive a health inequali...
Shift in Portuguese Pediatric Vaccination Policy: Evolving Perspectives on Risk and Benefit

By João L. Carapinha

April 10, 2026

Portuguese Pediatric Vaccination is now restricted to children with specific high-risk conditions, following the exact approach recommended by pharmaceutical experts in 2021. Portuguese health authorities have abandoned universal COVID-19 vaccination for children, limiting the program to those ag...